To examine research on variant reclassification within medical genetics over the past decade, focusing on the frequency and outcomes of reclassification until October 2025.
Key Findings:
Variant reclassification rates varied widely from 3.6% to 83.6%, indicating significant variability in practices.
48.7% of studies focused on variants of uncertain significance (VUS), highlighting a critical area of concern.
Main fields of study were oncology and cardiology, with limited research in endocrinology and obesity, suggesting a gap in knowledge.
Reclassification methods included literature review, functional studies, in silico predictions, segregation analysis, and machine learning, showcasing diverse approaches.
Interpretation:
The dynamic nature of genomic knowledge necessitates ongoing reclassification of genetic variants, which is crucial for accurate clinical decision-making and improving patient outcomes.
Limitations:
Limited understanding of reclassification practices in endocrinology, which may affect patient care.
Absence of standardized guidelines for recontact and reclassification protocols, leading to inconsistencies in practice.
Conclusion:
Routine reinterpretation and reanalysis of genetic variants can lead to significant improvements in clinical outcomes, underscoring the need for structured processes in variant reclassification to enhance patient care.
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
